Swiss Agency for Therapeutic Products (Swissmedic), has approved Santhera Pharmaceuticals’ drug candidate AGAMREE (vamorolone) for the treatment of Duchenne muscular dystrophy (DMD) in patients four years of age and older. The marks Santhera’s seventh global marketing approval and grants the company a 15-year exclusivity period under Swiss orphan drug status. Launching in Switzerland is anticipated later in 2026.
The Swissmedic has approved AGAMREE in Switzerland based on the data…
